Cephalon to pay $425M for improper drug marketing
Cephalon to pay $425M for improper drug marketing Save Email Print
Posted: 12:27 PM Sep 29, 2008
Last Updated: 12:27 PM Sep 29, 2008

A | A | A

PHILADELPHIA (AP) -- Drug maker Cephalon has completed a previously announced $425 million civil settlement with federal authorities over off-label drug marketing.

Federal authorities in Philadelphia say Cephalon Inc. marketed three drugs for uses other than what they were federally approved for. Cephalon disclosed the tentative settlement last November.

Authorities say Cephalon marketed one of the drugs, Actiq, for maladies including migraines and injuries. But authorities say the fentanyl lollipop is a highly addictive narcotic approved only for certain cancer patients.

The suburban Philadelphia company has signed an agreement to plead guilty to one count of distribution of misbranded drugs.

(Copyright 2008 by The Associated Press. All Rights Reserved.)

More Stories
How safe and effective are sunscreens?

Tennessee labs test for more disease than normal

HPV vaccine for men?

Volunteering for medical research

New HIV map finds cases heavy in the South

FDA says Zicam nasal spray can cause loss of smell

Local healthcare reform debate

WHO raising H1N1 flu alert to highest level.

Post Your Comments
First Name:
Location:
Enter Comments: characters left
Email (optional):
By posting this comment I have read and agree to the Terms of Use and Privacy Policy:
You must agree to the Terms of Service to continue.
Currently
Local Radar
Radar